PainChek Eyes US Market with FDA Application

PainChek Ltd (AU:PCK) has released an update.

PainChek Limited has applied for FDA De Novo clearance for its Adult App, a groundbreaking smartphone-based pain assessment tool targeting the US aged care market. With successful validation studies and strategic partnerships, the company aims to tap into a potential $85 million annual revenue opportunity in the world’s largest long-term care market. This move not only strengthens its position in the US but also paves the way for future expansion into broader market segments.

For further insights into AU:PCK stock, check out TipRanks’ Stock Analysis page.